and highly selective OGA inhibitor, Thiamet-G, on OGT and OGA mRNA and protein levels, was systematically studied in different cell types. The authors observed that OGA is more sensitive than OGT to O-GlcNAc levels. Increases in OGA expression were not due to stabilization of OGA mRNA or protein, suggesting regulation of OGA mRNA via transcription, through as yet unknown mechanisms.
O-GlcNAcylation is generally presented as a glycosylation that occurs only in the cytosol, the nucleus, and to a lesser extent, in mitochondria, in contrast to "classical" and complex Nand O-glycosylations that take place in the endoplasmic reticulum and the Golgi apparatus, and that modify transmembrane, secreted and organelle-confined proteins. However, biology is often made of exceptions to rules, and O-GlcNAcylation of protein extracellular domains has been demonstrated in Drosophila (6) . In this Research Topic, Nagnan-Le Meillour et al. (7) provide original data indicating that olfactory binding proteins (OBPs) secreted in pig nasal mucus are also modified by O-GlcNAc. They identified and cloned a conserved eOGT (EGF domain-specific OGT) in Sus scrofa and proposed that O-GlcNAcylation of OBPs could finely modulate their binding specificities for odors and pheromones.
Increased O-GlcNAcylation is involved in insulin resistance associated with diabetes and obesity (2) . The adipose cell plays a central role in the regulation of energy homeostasis, in particular, through its capacity to secrete adipokines that modulate insulin sensitivity and pro-inflammatory cytokines. Wollaston-Hayden et al. (8) show that O-GlcNAc modulates the transcript levels of multiple secreted proteins in rodent adipocytes, and propose that O-GlcNAcylation of transcription factors such as Sp1 plays a role in adipokines gene transcription during insulin resistance.
Whereas OGT or OGA knock down is lethal in higher eukaryotes, ogt1 and oga1 null C. elegans are viable. Taking advantage of this model organism, Ghosh et al. (9) investigated the consequences of OGT or OGA ablation, and showed that disruption in O-GlcNAc cycling alters nucleotide sugar production, overall glycan composition and transcription of genes encoding key members of the HBP pathway.
Although more than 1000 proteins are already known targets for O-GlcNAcylation, it is likely that numerous O-GlcNAcylated www.frontiersin.org proteins remain to be identified. In addition, one of the fascinating features of O-GlcNAc is its complex interplay with phosphorylation (1), either through regulation of phosphorylation at adjacent sites or by direct competition between O-GlcNAcylation and phosphorylation for the same site (the so-called Yin-Yang mechanism). In a Methods article, CieniewskiBernard et al. (10) describe the development of a multiplex, fluorescence-based proteomic strategy that permits to detect O-GlcNAcylated proteins, phosphoproteins, and the whole proteome on the same bi-dimensional gel.
This Research Topic also includes a number of reviews on some of the important biological and pathophysiological questions linked to O-GlcNAcylation. The perturbation of the O-GlcNAc cycle recently appeared as a hallmark of cancer cells (11) . Jóźwiak et al. (12) review the role of O-GlcNAc in metabolic reprograming of cancer cells, through modification of metabolic enzymes, signaling proteins, and transcription factors, and Chaiyawat et al. (13) discuss these alterations specifically in breast and colorectal cancers. Epigenetic alterations also characterize numerous tumors, and recent data reviewed by Dehennaut et al. (14) reveal the involvement of O-GlcNAcylation as an epigenetic mark, and its role in chromatin remodeling and DNA methylation.
Numerous studies have provided evidence that O-GlcNAc negatively regulates insulin signaling (2), highlighting a link between hyperglycemia, insulin resistance, and glucotoxicity. Zhang et al. (15) review the implication of O-GlcNAcylation of signaling components and transcription factors in normal liver metabolism and in liver diseases, including insulin resistance, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
In a mini review, Benahmed et al. (16) also discuss the role of transcription factors in the control of energy metabolism, and more specifically the antagonistic relationships between ChREBP, which controls the expression of glycolytic and lipogenic genes, and the nuclear receptor FXR, which controls bile acid metabolism involved in gut-liver homeostasis. Interestingly, both transcription factors are modified by O-GlcNAcylation, although the consequences of this modification on ChREBP-FXR interaction remain to be explored.
Finally, as several lines of evidence indicate that OGlcNAcylation regulates immune processes and may participate in hyperglycemia-associated inflammation, Baudoin and Issad (17) review the pro-and anti-inflammatory effects of O-GlcNAc, which may appear contradictory depending on cell types and pathophysiological situations. The field reviewed by these authors illustrates the complexity of signaling pathway regulation by O-GlcNAcylation. The control of inflammatory processes by O-GlcNAcylation is one of the innumerable Terra incognita to be explored.
Although not all aspects of O-GlcNAc biology could be presented in the Research Topic, we hope that it will excite the curiosity and stimulate the interest of young scientists for this ever-expanding, fascinating field.
